Figure 1: BLM deficiency is associated with CDA deficiency and pyrimidine pool imbalance.

(a) CDA mRNA and protein levels determined by real-time quantitative PCR and western blotting, respectively, in BS, GFP-BLM and GFP-BLMI841T cells (upper panels), in HeLash-siBLM and HeLaV-siCtrl cells (middle panels) and in human embryonic kidney HEK293sh-siBLM and HEK293V-siCtrl cells (lower panels). Error bars represent the s.e.m. of three independent experiments. The significance of differences was assessed by Student's t-tests. (b) Analysis of CDA promoter activity based on the luciferase assay in BS, GFP-BLM and GFP-BLMI841T cells. Firefly luciferase activity was normalized with respect to that of the Renilla luciferase expressed from a control vector introduced by co-transfection. Error bars represent the s.e.m. of seven independent experiments. The significance of differences was assessed by Student's t-tests. (c) Deoxycytidine triphosphate (dCTP) and deoxythymidine (dTTP) levels in BS and GFP-BLM cells. Error bars represent the s.e.m. of seven independent experiments. The significance of differences was assessed by Student's t-tests (upper panels). Deoxyadenosine triphosphate (dATP) and deoxyguanosine triphosphate (dGTP) levels in BS-GFP and GFP-BLM cells. Error bars represent the s.e.m. of three independent experiments (lower panels).